Advancing next generation approaches for diseases with unmet need

• Unmet need in obesity treatment still exists: Despite limitations and side effects, weight loss drugs represent more than $6 billion in annual revenues globally, with projections reaching $150 billion by 2030 (Reuters). CinRx’s CinCo, CinFina, is advancing new approaches to treating obesity and preserving lean muscle mass.
• Validating data across lead obesity programs: Recently presented at Obesity Week in November, CinFina’s CIN-110’s ability to safely and tolerably reduce caloric intake while quickly decreasing body weight after just a single dose positions it as a target=”_blank” high-potential treatment candidate. CIN-109 also produced meaningful weight loss and was well-tolerated across all dose levels in Phase 1 multiple ascending dose study, including at the highest dose tested, where most weight loss was due to a reduction in fat mass while increasing lean mass.
• The CinRx Difference—a successful “hub and spoke” model: CinRx’s portfolio of CinCos are centrally funded and managed by a team of scientific, technical, and drug development experts with decades of experience. Among the CinCos, are CinFina, CinDome and CinPhloro.
• Key Events in 2025: Additional data expected for CinFina’s CIN-110 Phase 1 single ascending dose (SAD) study; CinPhloro’s ongoing Phase 2 enviva study of CIN-103 for IBS-D evaluating the safety, efficacy and tolerability.